Date:2/4/2010

1,160,809 Shareholders’ equity 711,138 503,247 ------- ------- Total liabilities and shareholders’ equity $1,718,787 $1,664,056 ========== ========== METTLER-TOLEDO INTERNATIONAL INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (amounts in thousands) (unaudited) Three months ended Twelve months ended December 31, December 31, 2009 2008 2009 2008 Cash flows from operating activities: Net earnings $69,438 $62,924 $172,593 $202,778 Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation 7,708 6,793 29,634 28,987 Amortization 3,110 2,753 11,844 10,553 Deferred tax provision 19,539 12,094 3,766 4,137 Excess tax benefits from share-based payment arrangements (1,528) (610) (2,137) (1,609) Other 3,048 1,232 11,533 5,339 Increase (decrease) in cash resulting from changes in operating assets and liabilities (57,185) (22,662) 5,372 (27,036) ------- ------- ----- ------- Net cash provided by operating activities 44,130 62,524 232,605 223,149 ------ ------
'/>"/>

SOURCE Mettler-Toledo International Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Industrial Conference
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
9. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers